Sun Pharma temporary pause in release of batches from Mohali until US FDA mandated measures are implemented

Sun Pharma has received a letter titled “CONSENT DECREE CORRESPONDENCE/NON-COMPLIANCE LETTER” from the US FDA. US FDA has directed the Company to take certain corrective actions at the Mohali facility before releasing further final product batches into the US. These actions include, among others, retaining an independent CGMP expert to conduct batch certifications of drugs manufactured at the Mohali facility. The Company is taking required corrective steps, but there will be a temporary pause in release of batches from Mohali until US FDA mandated measures are implemented. US shipments from Mohali will resume once these measures are in place.

Comments

Popular posts from this blog

Rail Vikas Nigam limited received Letter of Award from National Highway Authority of India (NHAI) for “Construction of Six Lane Elevated Kona Expressway from km 0.145 to km 7.337 of NH-117 in the state of West Bengal on EPC mode

Carysil Limited renews Contract with “KARRAN INC. USA” for supply of Quartz Kitchen Sink for value of ~ USD 68 million over the period of 5 years

Chemicals Result Summary Jun-2024